Objective: To assess women’s perception of a combined oral contraceptive (COC) containing drospirenone 3 mg/ethinylestradiol (EE) 20 μg administered in the conventional 21/7 regimen (drospirenone 3mg/EE 20 μg 21/7 regimen [Yasminelle®]) in clinical practice.
Methods: This questionnaire-based study was performed in 12 European countries and included women who had been taking the drospirenone 3 mg/EE 20 μg 21/7 regimen COC for ≥3 months.
Results: Of 16 461 completed questionnaires, 12 277 were from women who had been using the drospirenone 3 mg/EE 20 μg 21/7 regimen COC for ≥3 months — 34% of women were new users of COCs and 65% had switched from alternative contraceptive brands. The mean age of these respondents was approximately 27 years. Seventy percent of women who indicated that they had skin problems before taking the drospirenone 3 mg/EE 20 μg 21/7 regimen COC responded that their skin had improved with treatment (3030/4305). Sixty-nine percent of women who had switched to the drospirenone 3 mg/EE 20 μg 21/7 regimen COC because of weight problems with their previous method of contraception responded that they had experienced weight loss (1205/1745). Approximately 95% of respondents said they were satisfied with the drospirenone 3 mg/EE 20 μg 21/7 regimen COC. Moreover, 83% of respondents said they would recommend this COC to a friend.
Conclusion: There were high levels of perceived satisfaction with the drospirenone 3 mg/EE 20 μg 21/7 regimen COC. The reported effects on weight loss (due to decreased water retention) and skin problems are consistent with the antimineralocorticoid and antiandrogenic benefits of drospirenone-containing COCs.
Acne Combine Oral Contraceptive Premenstrual Symptom Weight Problem Drospirenone
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.
Bayer Schering Pharma AG, Berlin, Germany provided funding for this study and were involved in conducting the analysis and also reviewing the manuscript. The author would like to acknowledge Anne Zimmermann for her conduct and analysis of the study, and Richard Glover for his editorial assistance with the development of this manuscript, with the financial support of Bayer Schering Pharma AG. The author has received an honorarium from Bayer Schering Pharma AG for presentation of the content of this study at a conference.
Shvarts S, Besinque K, Atkinson R, et al. New advances in contraception. Insights 2002: 11-22Google Scholar
Trussell J. Contraceptive efficacy. In: Hatcher RA, Trussell J, Stewart F, et al., editors. Contraceptive technology. New York: Ardent Media, 2004: 355–63Google Scholar
Kaunitz AM. Combined oral contraception with desogestrel/ ethinyl estradiol: tolerability profile. Am J Obstet Gynecol 1993; 168: 1028–33PubMedGoogle Scholar
Rosenberg MJ, Waugh MS, Meehan TE. Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation. Contraception 1995; 51: 283–8PubMedCrossRefGoogle Scholar
Fuchs N, Prinz H, Koch U. Attitudes to current oral contraceptive use and future developments: the women’s perspective. Eur J Contracept Reprod Health Care 1996; 1: 275–84PubMedCrossRefGoogle Scholar
Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol 1998; 179: 577–82PubMedCrossRefGoogle Scholar
Cibula D, Karck U, Weidenhammer HG, et al. Efficacy and safety of a low-dose 21-day combined oral contraceptive containing ethinylestradiol 20 μg and drospirenone 3mg. Clin Drug Investig 2006; 26: 143–50PubMedCrossRefGoogle Scholar
Gruber DM, Huber JC, Melis GB, et al. A comparison of the cycle control, safety, and efficacy profile of a 21-day regimen of ethinylestradiol 20 μg and drospirenone 3 mg with a 21-day regimen of ethinylestradiol 20 μg and desogestrel 150 μg. Treat Endocrinol 2006; 5: 115–21PubMedCrossRefGoogle Scholar
Muhn P, Krattenmacher R, Beier S, et al. Drospirenone: a novel progestogen with antimineralocorticoid and anti-androgenic activity. Pharmacological characterization in animal models. Contraception 1995; 51: 99–10PubMedCrossRefGoogle Scholar
Fuhrmann U, Krattenmacher R, Slater EP, et al. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception 1996; 54: 243–51PubMedCrossRefGoogle Scholar
Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000; 62: 29–38PubMedCrossRefGoogle Scholar
van Vloten WA, van Haselen CW, van Zuuren EJ, et al. The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis 2002; 69: 2–15PubMedGoogle Scholar
Thorneycroft H, Gollnick H, Schellschmidt I. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment. Cutis 2004; 74: 123–30PubMedGoogle Scholar
Lucky AW, Koltun W, Thiboutot D, et al. 3 mg drospirenone/20 μg EE 24/4 in the treatment of acne vulgaris: lesion counts, subject self-assessment. Cutis 2008; 82: 143–50PubMedGoogle Scholar
Koltun W, Lucky AW, Thiboutot D, et al. Efficacy and safety of 3 mg drospirenone/20 μg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial. Contraception 2008; 77: 249–56PubMedCrossRefGoogle Scholar
Maloney JM, Dietze P, Watson D, et al. A randomized controlled trial of 3 mg drospirenone/20 μg EE 24/4 COC in the treatment of acne vulgaris. Obstet Gynecol 2008; 112: 773–81PubMedCrossRefGoogle Scholar
Schultz-Zehden B, Boschitsch E. User experience with an oral contraceptive containing ethinylestradiol 30 mug and drospirenone 3 mg (Yasmin®) in clinical practice. Treat Endocrinol 2006; 5: 251–6PubMedCrossRefGoogle Scholar
Skouby SO. Contraceptive use and behavior in the 21st century: a comprehensive study across five European countries. Eur J Contracept Reprod Health Care 2004; 9: 57–68PubMedCrossRefGoogle Scholar
Gallo MF, Nanda K, Grimes DA, et al. 20 mcg versus >20 mcg estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev 2005; (2): CD003989Google Scholar
Gallo MF, Nanda K, Grimes DA, et al. Twenty micrograms versus >20 micrograms estrogen oral contraceptives for contraception: systematic review of randomized controlled trials. Contraception 2005; 71: 162–9PubMedCrossRefGoogle Scholar
Freeman EW, Kroll R, Rapkin A, et al. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gend Based Med 2001; 10: 561–9PubMedCrossRefGoogle Scholar
Brown C, Ling F, Wan J. A new monophasic oral contraceptive containing drospirenone: effect on premenstrual symptoms. J Reprod Med 2002; 47: 14–22PubMedGoogle Scholar
Borenstein J, Yu HT, Wade S, et al. Effect of an oral contraceptive containing ethinyl estradiol and drospirenone on premenstrual symptomatology and health-related quality of life. J Reprod Med 2003; 48: 79–85PubMedGoogle Scholar
Pearlstein TB, Bachmann GA, Zacur HA, et al. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 2005; 72: 414–21PubMedCrossRefGoogle Scholar
Yonkers KA, Brown C, Pearlstein TB, et al. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet and Gynecol 2005; 106: 492–501CrossRefGoogle Scholar
Gallo MF, Lopez LM, Grimes DA, et al. Combination contraceptives: effects on weight. Cochrane Database Syst Rev 2006; (1): CD003987Google Scholar